Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Surufatinib · Tislelizumab · Concurrent Chemoradiotherapy · Consolidation Therapy · Non-small Cell Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China
Contact: Study coordinator (Hui Liu, Professor) · liuhui@sysucc.org.cn · 02087343031

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

Toripalimab · Surufatinib · Chemoradiotherapy

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Toripalimab · Surufatinib · Neoadjuvant Immunochemotherapy

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC

NSCLC (Non-small Cell Lung Cancer)

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma

Osteosarcoma

Abroad (travel likely)RecruitingPHASE2

Hangzhou, China